Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 64

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 64
---
 of Directors (the “ Board”) on April 9, 2025.
This MD& A is dated April 9, 2025.

About
Forward-Looking Statements

Certain
statements in this MD& A, referred to herein as “forward-looking statements”, constitute “forward-looking statements”
within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information”
under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances,
events, activities, or developments that could or may or will occur are forward-looking statements. When used in this MD& A, words
such as “anticipate”, “assume”, “believe”, “could”, “expect”, “forecast”,
“future”, “goal”, “guidance”, “intend”, “likely”, “may”, “would”
or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify
forward-looking statements, although not all forward-looking statements include such words.

Forward-looking
statements are based on the opinions and estimates of the Company as of the date of this MD& A, and they are subject to known and
unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements
to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the factors
described in “ Risk Factors” and those relating to: the Company’s patented technologies and value-driving products,
and development thereof; the extraction, production and commercialization of active ingredients from natural sources and our ability
to successfully market related products; the successful development and marketing of our oat-based pipeline products, including oat-beta
glucan, avenanthramides and beta glucan from yeast, as well as such products’ capability to address unmet needs within the nutraceuticals
markets; Macrilen ®

  44  

Forward-looking
statements involve known and unknown risks and uncertainties, and other factors which may cause the actual results, performance or achievements
stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
information. Such risks and uncertainties include, among others: the Company’s present and future business strategies; operations
and performance within expected ranges; anticipated future cash flows; local and global economic conditions and the environment in which
the Company operates; the